Taisho Pharmaceutical Co. said Wednesday its group net profit fell 25.1 percent in the fiscal first half from the previous year to 15.56 billion yen, hit by poor sales of its mainstay nutritional supplement drinks.
The drug maker said its group pretax profit fell 22.8 percent in the April-September period to 26.32 billion yen, on sales of 134.32 billion yen, down 4.3 percent.
Per-share net profit fell to 50.47 yen from 66.59 yen in the same period last year.
The company said sales of its Lipovitan nutrient drinks fell 4.6 percent to 51.2 billion yen and those of Pabron cold medicines dropped 20.6 percent to 9.2 billion yen. Its prescription drug sales edged 2.1 percent higher to 800 million yen.